SCHEMBL8101244

SCHEMBL8101244

CCC(Oc1ccccc1)C(=O)Nc1ccc2[nH]c3c(c2c1)CC(NC(C)c1cccc(I)c1)CC3

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
HTR1A P08908 2/20 0.37
HTR1B P28222 2/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
HTR1E P28566 1/20 0.37
HTR7 P34969 1/20 0.37
OPRM1 P35372 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
HTR1D P28221 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTR1F P30939 1/20 0.37
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8101236 0.85 LMNA (0.37) LMNAHTTHTR1AHTR1BDRD2
Hydrochloric Acid SCHEMBL8110501 0.81 HTR1A (0.43) LMNAHTR1AHTR1BDRD2DRD4
SCHEMBL8110482 0.80 LMNA (0.45) LMNAHTTHSD17B10HTR1FALDH1A1
Hydrochloric Acid SCHEMBL8101396 0.71 VPS4B (0.42) LMNAHTR1AHTR1BDRD2DRD4
Mandelic Acid SCHEMBL8116454 0.69 POLB (0.42) LMNAHTTALDH1A1SMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL8110496 0.69 RB1 (0.44) HTR1AHTR1BDRD2DRD4HTR1E
SCHEMBL8101124 0.69 JAK2 (0.47) LMNAHTR1AHTR1BDRD2DRD4
SCHEMBL2494316 0.68 VPS4B (0.51) HTR1AHTR1BDRD2DRD4HTR1E
SCHEMBL2494312 0.68 VPS4B (0.51) HTR1AHTR1BDRD2DRD4HTR1E
SCHEMBL2493068 0.68 VPS4B (0.51) HTR1AHTR1BDRD2DRD4HTR1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
EP-0749962-B1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles LILLY CO ELI (US) 2000-11-02 EP disclosed
US-5814653-A SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS ELI LILLY AND COMPANY (US) 1998-09-29 US disclosed
US-5708187-A MIGRANE HEADACHES ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
EP-0749962-A1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles ELI LILLY AND COMPANY (US) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D LMNA 4061/4885HTT 131/4885HTR1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.